Panbela Therapeutics Inc. (PBLA)
$0.00
$-0.32
(-99.97%)
As on 03-Sep-2026 16:00EDT
Market cap
$0 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
3.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-8 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.2
-
Debt to Equity
-0.2
-
Book Value
$--
-
EPS
$-7.3
-
Face value
--
-
Shares outstanding
4,854,831
10 Years Aggregate
CFO
$-65.92 Mln
EBITDA
$-127.26 Mln
Net Profit
$-107.72 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Panbela Therapeutics (PBLA)
| -- | -- | -- | -- | -98.5 | -98.2 | -- |
|
BSE Sensex*
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|
|
Panbela Therapeutics (PBLA)
| -98.1 | -99.0 | -51.4 | -15.2 | 19.7 | -65.0 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 22.0 | 15.8 | 14.4 | 5.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Panbela Therapeutics (PBLA)
|
0.0 | 0.0 | 0.0 | -27.9 | -- | -- | -- | 3.2 |
| 84.8 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 268.4 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 72.4 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 59.0 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 110.2 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 355.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 541.4 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 592.0 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 124.0 | 9,808.7 | 0.0 | -450.1 | -- | -44.6 | -- | 8.4 |
Shareholding Pattern
View DetailsAbout Panbela Therapeutics (PBLA)
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin... (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota. Read more
-
CEO, President & Director
Dr. Jennifer K. Simpson CRNP, M.S.N., Ph.D.
-
CEO, President & Director
Dr. Jennifer K. Simpson CRNP, M.S.N., Ph.D.
-
Headquarters
Waconia, MN
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Panbela Therapeutics (PBLA)
What is the current share price of Panbela Therapeutics Inc (PBLA) Today?
The share price of Panbela Therapeutics Inc (PBLA) is $0.00 (NASDAQ) as of 03-Sep-2026 16:00 EDT. Panbela Therapeutics Inc (PBLA) has given a return of -98.49% in the last 3 years.
What is the current PB & PE ratio of Panbela Therapeutics Inc (PBLA)?
Since, TTM earnings of Panbela Therapeutics Inc (PBLA) is negative, P/E ratio is not available.
The P/B ratio of Panbela Therapeutics Inc (PBLA) is 3.22 times as on 27-Aug-2026, a 38 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2023 |
-0.11 |
-0.61 |
2022 |
0.00 |
0.00 |
2021 |
0.00 |
0.00 |
2020 |
-0.01 |
0.00 |
2019 |
0.00 |
0.02 |
What is the 52 Week High and Low of Panbela Therapeutics Inc (PBLA)?
The 52-week high and low of Panbela Therapeutics Inc (PBLA) are Rs 0.02 and Rs 0.00 as of 05-Sep-2026.
What is the market cap of Panbela Therapeutics Inc (PBLA)?
Panbela Therapeutics Inc (PBLA) has a market capitalisation of $ 0 Mln as on 27-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Panbela Therapeutics Inc (PBLA)?
Before investing in Panbela Therapeutics Inc (PBLA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.